Search research articles
Contact Us
Filters
Showing results (111-120 of 118) with videos related to
Page
of 12
Sort By:
You have reached the last page of results.
This site can display upto 118 results.
European Journal of Cancer (Oxford, England : 1990)
|
March 16, 2013
Borderline tumours of the ovary: A cohort study of the Arbeitsgmeinschaft Gynäkologische Onkologie (AGO) Study Group
Andreas du Bois, Nina Ewald-Riegler, Nikolaus de Gregorio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 3, 2025
Atezolizumab With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results From the Placebo-Controlled AGO-OVAR 2.29/ENGOT-ov34 Phase III Trial
Philipp Harter, Frederik Marmé, Andrés Redondo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 1, 2021
Ovarian Cancer-Specific <i>BRCA</i>-like Copy-Number Aberration Classifiers Detect Mutations Associated with Homologous Recombination Deficiency in the AGO-TR1 Trial
Philip C Schouten, Lisa Richters, Daniel J Vis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 4, 2022
Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial
Jacobus Pfisterer, Florence Joly, Gunnar Kristensen, et al.
Journal of the National Cancer Institute
|
April 25, 2026
Health-related quality of life in patients with newly diagnosed advanced ovarian cancer receiving maintenance olaparib plus bevacizumab (PAOLA-1/ENGOT-ov25)
Florence Joly, Amélie Anota, Sylvie Chabaud, et al.
Journal of Medical Genetics
|
April 14, 2019
Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: results of the observational AGO-TR1 study (NCT02222883)
Jan Hauke, Eric Hahnen, Stephanie Schneider, et al.
Plos One
|
October 21, 2017
Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1)
Philipp Harter, Jan Hauke, Florian Heitz, et al.
NPJ Genomic Medicine
|
March 5, 2024
Genome-wide association analyses of ovarian cancer patients undergoing primary debulking surgery identify candidate genes for residual disease
Dhanya Ramachandran, Jonathan P Tyrer, Stefan Kommoss, et al.
Page
of 12
Search research articles
Search
Showing results (111-120 of 118) with videos related to
Sort By:
Page
of 12
You have reached the last page of results.
This site can display upto 118 results.
European Journal of Cancer (Oxford, England : 1990)
|
March 16, 2013
Borderline tumours of the ovary: A cohort study of the Arbeitsgmeinschaft Gynäkologische Onkologie (AGO) Study Group
Andreas du Bois, Nina Ewald-Riegler, Nikolaus de Gregorio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 3, 2025
Atezolizumab With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results From the Placebo-Controlled AGO-OVAR 2.29/ENGOT-ov34 Phase III Trial
Philipp Harter, Frederik Marmé, Andrés Redondo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 1, 2021
Ovarian Cancer-Specific <i>BRCA</i>-like Copy-Number Aberration Classifiers Detect Mutations Associated with Homologous Recombination Deficiency in the AGO-TR1 Trial
Philip C Schouten, Lisa Richters, Daniel J Vis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 4, 2022
Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial
Jacobus Pfisterer, Florence Joly, Gunnar Kristensen, et al.
Journal of the National Cancer Institute
|
April 25, 2026
Health-related quality of life in patients with newly diagnosed advanced ovarian cancer receiving maintenance olaparib plus bevacizumab (PAOLA-1/ENGOT-ov25)
Florence Joly, Amélie Anota, Sylvie Chabaud, et al.
Journal of Medical Genetics
|
April 14, 2019
Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: results of the observational AGO-TR1 study (NCT02222883)
Jan Hauke, Eric Hahnen, Stephanie Schneider, et al.
Plos One
|
October 21, 2017
Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1)
Philipp Harter, Jan Hauke, Florian Heitz, et al.
NPJ Genomic Medicine
|
March 5, 2024
Genome-wide association analyses of ovarian cancer patients undergoing primary debulking surgery identify candidate genes for residual disease
Dhanya Ramachandran, Jonathan P Tyrer, Stefan Kommoss, et al.
Page
of 12